SKAN, the Wellcome Sanger Institute and University of Newcastle to study early stem cell mutations in rare blood disorder
SKAN Research Trust (SKAN), promoted by Indian entrepreneur Ashok Soota, today announced a joint research project with the UK-based Wellcome Sanger Institute (Sanger Institute) and University of Newcastle (Newcastle), to study early somatic mutations in blood stem cells that researchers believe drive several…
Groundbreaking New Blood Test Offers Early Pancreatic Cancer Diagnosis Study Says
As reported in today’s issue of the journal Metabolites, researchers at Metabolomycs, a California-based biotechnology company, for the first time applied targeted mass spectrometry to show that pancreatic cancer arises through changes in cellular metabolism and that these changes can be measured with…
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in…
Tigerlily Foundation and Labcorp Launch I AM INCLUDED Framework to Increase Clinical Trial Diversity, Accelerate Delivery of Innovative Cancer Treatments
Today, the Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, and Labcorp, a global leader of innovative and comprehensive laboratory services, announced the launch of I AM INCLUDED, a co-developed, modernized, multi-stakeholder framework for sharing best practices of U.S. diverse clinical trial…
K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer
K36 Therapeutics, Inc. (“K36”), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple myeloma, today announced that Benjamin Winograd, MD, PhD, has been appointed Chief Medical Officer to lead the Medical and Clinical teams. Dr. Winograd joins…
MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U.S. with Outstanding Safety Results
On November 9, 2023, ImmVira announced the successful completion of Phase I clinical study conducted on late-stage patients with various tumor types for our intravenous oncolytic product, MVR-T3011 IV, in the United States. This milestone was marked by the product’s exceptional safety results…
Genetics of Nearby Healthy Tissue May Help Catch Lung Cancer’s Return
Genetic information collected from seemingly healthy tissue near lung tumors may be a better predictor of whether cancer will come back after treatment than analysis of the tumors themselves, according to new research led by NYU Langone Health and its…
Deep Bio Joins CancerX to Revolutionize Cancer Diagnosis and Prognosis with AI Expertise
Deep Bio, a leading AI healthcare company specializing in deep learning and cancer pathology, is proud to announce its participation in the groundbreaking CancerX initiative, a public-private partnership unveiled earlier this year as part of the White House Cancer Moonshot…
Oncoclínicas opens first Cancer Center in Brazil as an International Collaborative Member of Dana-Farber Cancer Institute
Oncoclínicas&Co, the largest group dedicated to cancer in Latin America, and Dana-Farber Cancer Institute, a Harvard Medical School affiliated teaching hospital and one of the world’s leading cancer treatment and oncology research institutions, announce the expansion of their collaboration with the opening of…
Prostate Cancer Diagnosis Just Got Easier with CE Mark Certification of Lucida Medical’s New AI Software
Lucida Medical Ltd, a Cambridge-based start-up company dedicated to improving cancer diagnosis, has announced Class IIb CE certification for its AI-based prostate cancer detection software, Prostate Intelligence™ (Pi™). Built with leading clinicians and UK NHS hospitals, the CE mark means the software can…
